GAINESVILLE, Fla., July 21, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent related to the Company's proprietary NIMBUS® antimicrobial technology.
The forthcoming patent protects a process of post-polymerization bonding and is the fourth such recognition of propriety ownership secured by Quick-Med for NIMBUS.
"Our latest Notice of Allowance further safeguards the method of use and competitive position surrounding our proprietary NIMBUS technology," said J. Ladd Greeno, Quick-Med's CEO. "We developed NIMBUS as a breakthrough alternative to today's leaching antimicrobials, which are associated with adverse effects. We are confident that NIMBUS has the potential to provide cost-savings, increased safety, superior performance and improvement in wound care outcomes that will benefit patients and medical professionals in a variety of healthcare and consumer settings."
The latest Notice of Allowance for NIMBUS protects the process used to bind a highly effective microbicidal property to specific substrates, as well as a very broad selection of substrate types and product applications. This post-polymerization bonding is a unique process in which the resulting material has a non-leachable microbicide firmly retained. The allowed claims of this application cover two polyelectrolyte antimicrobials: polydimethyl ammonium chloride and polyvinyl benzyl trimethyl ammonium chloride. The claims grant protection to the antimicrobial agent cleared by the FDA under de novo evaluation, also distinguishing the novelty of the technology.
The claims also include a full spectrum of products such as medical devices, wound dressings, burn dressings, blood transfer products, surgical apparel, military protective wear, and hygienic products such as wipes, diapers and feminine care.
A Notice of Allowance communicates the Patent Office's determination that the applicant is entitled to a patent under the law. The Company expects the new patent to be issued later this year.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.
© 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.